Illumina to Buy Back as Much as $75M in Stock | GenomeWeb
NEW YORK (GenomeWeb News) — Illumina plans to buy back as much as $75 million of its outstanding common stock over a six-month period, and has filed a trading plan to allow it to complete the transactions.
 
Earlier this month Illumina said it would use $200 million from a senior note sale to buy back its own stock.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.